Home - Products - Chromatin/Epigenetic - Epigenetic Reader Domain - Piflufolastat

Piflufolastat

CAS No. 1423758-00-2

Piflufolastat( —— )

Catalog No. M34569 CAS No. 1423758-00-2

Piflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	141	In Stock
5MG	117	In Stock
10MG	188	In Stock
25MG	432	In Stock
50MG	732	In Stock
100MG	1265	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Piflufolastat
Note

Research use only, not for human use.
Brief Description

Piflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation.
Description

Piflufolastat (DCFPYL) can be used to the preparation of piflufolastat F 18 (DCFPyL F-18). piflufolastat F 18. Piflufolastat F-18 is an 18F-labelled diagnostic imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA).
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Chromatin/Epigenetic
Target

Epigenetic Reader Domain
Recptor

Epigenetic Reader Domain | PSMA
Research Area

——
Indication

——

Chemical Information

CAS Number

1423758-00-2
Formula Weight

442.4
Molecular Formula

C18H23FN4O8
Purity

>98% (HPLC)
Solubility

——
SMILES

C(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)(=O)C=1C=CC(F)=NC1
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Keam SJ, et al. Piflufolastat F 18: Diagnostic First Approval. Mol Diagn Ther. 2021 Sep;25(5):647-656. ?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

GSK620

GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.
ZEN-3219

ZEN-3219 is a BET inhibitor, which has inhibitory effect on BRD4(BD1), BRD4(BD2) and BRD4(BD1BD2).
ODM-207

BET-IN-4 is a potent BRD4 inhibitor.

Sign In Join Free